At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Convalescent Plasmadrug
Likely dose
Convalescent Plasma 1 unitfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
In Brief
A Phase 2 clinical trial evaluating Convalescent Plasma for COVID-19. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedJun 2020
Primary CompletionJul 2020
Study CompletionMar 2021
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartApr 28, 2020
Primary CompletionJul 31, 2020
Study CompletionMar 12, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.0 years ago
Interventions
Convalescent Plasmadrug
Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.